Oncology Nursing News magazine interviewed Carl Harrington, president of the IWMF, to properly present the impact that the US FDA’s decision to approve imbruvica (ibrutinib) specifically for WM has on WM patients. He also discusses the significance of the IWMF in providing support to WM patients and in funding research.
Language
Language